1.
Aust J Gen Pract
; 53(3): 138-140, 2024 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38437657
2.
Australas J Dermatol
; 64(1): 131-137, 2023 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36514287
RESUMO
We present a case series of 13 patients, the first Australian single-centre study of bullous pemphigoid (BP) associated with immune checkpoint inhibitors (ICI): cytotoxic T-lymphocyte antigen (CTLA4) and programmed cell death receptor (PD1) inhibitors. All our patients achieved adequate control of BP with a combination of treatments including oral prednisolone, intravenous immunoglobulin, rituximab and omalizumab. The majority of patients ceased or interrupted immunotherapy treatment upon diagnosis of BP and greater tumour progression was seen in the cohort who ceased immunotherapy.
Assuntos
Inibidores de Checkpoint Imunológico , Penfigoide Bolhoso , Humanos , Austrália , Antígeno B7-H1/efeitos dos fármacos , Morte Celular , Penfigoide Bolhoso/etiologia , Penfigoide Bolhoso/patologia , Inibidores de Checkpoint Imunológico/efeitos adversos , Inibidores de Checkpoint Imunológico/uso terapêutico
3.
Aust Fam Physician
; 46(10): 744-745, 2017 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29036774